p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial

Annals of Oncology

Volumn 18, Issue 6, 2007, Pages 997-1003

  Di Leo, A ^a   Tanner, M ^b   Desmedt, C ^c   Paesmans, M ^c   Cardoso, F ^c   Durbecq, V ^c   Chan, S ^d   Perren, T ^e   Aapro, M ^f   Sotiriou, C ^c   Piccart, M J ^c   Larsimont, D ^c   Isola, J ^g  

^a Tuscany Cancer Institute   (Italy)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c JULES BORDET INSTITUTE   (Belgium)

^d NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f CLINIQUE DE GENOLIER   (Switzerland)

^g TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Cytotoxics; Molecular markers; Topoisomerase II alpha

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GENOMIC DNA; METHOTREXATE; MOLECULAR MARKER; PROTEIN P53;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA SEQUENCE; DRUG RESPONSE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WILD TYPE;

EID: 34447314153     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm075     Document Type: Article

References (21)

1. O'Connor PM, Jackman J, Bae I et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agent. Cancer res 1997; 57: 4285-4300.
2. Brown JM, Wouters BG, Apoptosis. p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999; 59: 1391-1399.
3. Geisler S. Lonning PE, Aas T et al. Influence of TP53 gene alterations and c-erB-2 expression on the response to treatment with doxorubicin in locally advanced, breast carcer. Cancer Res 2001; 61: 2505-2512.
4. Kandioler-Eckersberger D, Ludwig C, Rudas M et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients Clin Cancer Res 2000; 6: 50-56.
5. Chan S, Friedrichs K, Noel D et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341-2354.
6. Di Leo A, Chan S, Paesmans M et al. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent dexorubicin or single agent docetaxel. Breast Cancer Res Treat 2004; 86: 197-206.
7. Durbecq V, Paesmans M, Cardoso F et al. Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin of single-agent docetaxel. Mol Cancer Ther 2004; 3: 1207-1214.
8. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva, Zwitzerland: World Health Organization Offset Publication 1979.
9. Di Leo A, Larsimont D, Gancberg D, et al. HER-2 and topoisomerase II alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 2001; 12: 1081-1089.
10. Geisler S. Borresen Dale AL, Johnsen H et al. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 2003; 9: 5582-5588.
11. Andersson J, Larsson L, Klaar S et al. Worse survival for TP53 (p-53). mutated breast cancer patients receiving adjuvant CMF. Ann Oncol 2005; 16: 743-748.
12. Sjogren S, Inganas M, Norberg T et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996; 88: 173-182.
13. Miller LD, Smeds J, George J et al. An expression signature for p53 status in human breast cancer Predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005; 102: 13550-13555.
14. Mitchell KO, Ricci MS, Miyashita T et al. Bax is a transcriptional target and mediator of c-myc-induced apoptosis Cancer Res 2000: 60: 6318-6325.
15. Ceballos E, Delgado MD, Gutierrez P et al. c-Myc antagonizes the effect of p53 on apoptosis and p21 WAF1 trasactivation in K562 leukaemia cells. Oncogene 2000; 19: 2194-2204.
16. Xu Y, Yao L, Ouyang T, et al. p53 codon 72 polymorphism predicts to pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 2005; 11: 7328-7333.
17. Vikhanskaya F, Siddique MM, Lee MK et al. Evaluation the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs. Clin Cancer Res 2005; 11: 4348-4356.
18. Di Leo A, Isola J. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer patients: Are we at the end of the beginning? Clin Breast Cancer 2003; 4: 179-186.
19. Lynch BJ, Guinee DG, Holden JA. Human DNA topoisomerase II-alpha. a new marker of Cell Proliferation in invasive breast cancer. Hum Pathol 1997; 28: 1180-1188.
20. Durbeco V, Desmedt C, Paesmans M, et al. Correlation between topoisomerase-II alpha gene amplification and protein expression in HER-2 amplified breast cancer Int J Oncol 2004; 25: 1473-1479.
21. Bonnefoi H. Small randomized neo-adjuvant chemotherapy trials in breast cancer reporting on Pathological response more harm than good? Ann Oncol 2005: 16: 1407-1410.